Methylenedioxybenzylamphetamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
MDBZ, also known as 3,4-methylenedioxy-N-benzylamphetamine or as N-benzyl-MDA, is a chemical compound of the phenethylamine, amphetamine, MDxx, and N-benzylphenethylamine families related to MDA.[1][2] It is the N-benzyl derivative of MDA.[1][2]
- None
| Clinical data | |
|---|---|
| Other names | MDBZ; 3,4-Methylenedioxy-N-benzylamphetamine; N-Benzyl-MDA |
| Routes of administration | Oral[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H19NO2 |
| Molar mass | 269.344 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Use and effects
Chemistry
History
MDBZ was first described in the scientific literature by Alexander Shulgin and colleagues in 1980.[3] Subsequently, it was described in greater detail by Shulgin in his book PiHKAL (Phenethylamines I Have Known and Loved) in 1991.[1]
Society and culture
Popular culture
In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to MDBZ.[4]
Legal status
United Kingdom
MDBZ is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[5]